Determination of antibacterial selectivity of our best antichlamydials.

The data underlying Figs 3 and S8–S11. (A) Potency of selected top compounds in different cell lines infected with CTL2-GFP, as measured by bulk GFP fluorescence. Data are displayed in Fig 3A. (B) Growth inhibition by selected top compounds in different host cell lines. The data is based on measurements of bulk GFP fluorescence. Data are displayed in S8A and S8B Fig. (C) Toxicity of selected top compounds against different host cell lines. The data is based on measurements of bulk resorufin fluorescence. Data are displayed in Figs 3B and S9A and S9B. (D) Potency of selected top compounds in HeLa cells infected with the indicated Chlamydia strains, as measured by inclusion area. Data are displayed in Fig 3C. (E) Effect of top compounds on the growth of five species of gut bacteria in dilution assays. Data are displayed in Figs 3D and S10A. (F) Effect of top compounds on the growth of microbiota species in comparison to their IC50 and MIC against Chlamydia trachomatis (as reported in S2F Data and S3H Data). (G) Effect of c1e–c3e on the growth of additional gut bacteria species in radial diffusion assays. Data are displayed in S10B Fig. (H) Effect of top compounds on the growth of four species of the vaginal microbiota in dilution assays. Data are displayed in S11 Fig. (XLSX)